On July 17, 2018, Standard & Poor’s Ratings Services affirmed its 'BB+/B' issuer credit ratings on Ibudalanasjodur (Housing Financing Fund, HFF). The outlook is revised to stable.  

For further information, please see the attached file.

Attachment